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Summary
Objective: To study the temporal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the STR/ort mouse
model of osteoarthritis, using in situ hybridization with oligonucleotide probes and specific antisera for each protein.
Methods: In situ hybridization and immunolocalization experiments were performed on serial cryosections of knee joints from STR/ort and
control CBA mice. The mRNA was localized using digoxygenin-labeled probes.
Results: MMP2, MMP3, MMP7, MMP9, MMP13, MT1-MMP and TIMP2 mRNA was detected in the tibial articular chondrocytes of STR/ort
mice at all ages (12, 18, 24, 30 and 35 weeks). Levels were always higher than in age-matched CBA mice. Neither MMP8 nor TIMP1 mRNA
was detected in murine cartilage. The location and distribution of each of the MMP mRNA transcripts varied within the tibial plateau.
Immunolocalization consistently detected MMP3 and MT1-MMP in articular cartilage and MMP13 in calcified cartilage. Other proteases and
their inhibitors were not detected in either of these cartilages but MMP2 and MMP9 were immunolocalized in bone marrow cells and growth
cartilage respectively.
Conclusion: Expression of all the detected MMPs and TIMP-2 is up-regulated in STR/ort mice at the mRNA level. However, failure to detect
protein expression for MMPs 2, 7, 9, 13 and TIMPs 1 and 2 in murine chondrocytes by immunohistochemistry indicates that the changes in
mRNA levels in STR/ort mice must be interpreted with caution. © 2002 OsteoArthritis Research Society International. Published by Elsevier
Science Ltd. All rights reserved.
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The limited availability of normal human joint tissues and of
tissues from patients with early osteoarthritis (OA) impede
study of the disease in man. What causes the disease is
unknown. Thus many animal models have been developed
to investigate mechanisms underlying the disease. For
example, degenerative lesions can be induced chemically,
by the injection of toxins or enzymes, or by surgical
disruption of the joint mechanics1. In marked contrast to
these models, STR/ort mice are genetically predisposed to
develop an OA-like lesion in the medial tibial cartilage.
More than 85% of male STR/ort mice show signs of
cartilage degeneration by 6 months of age2–4. Usually,722fibrillation of articular cartilage starts on the medial tibial
plateau adjacent to the attachment site of the anterior
cruciate ligament and progresses to erosion, fissures
and cartilage loss5. The cartilage on the lateral tibial
plateau sometimes develops lesions, but these are usually
less severe and less frequent than those on the medial
plateau4. Changes in chondrocyte expression of cytokine,
growth factors and matrix components have been identified
early in the disease6,7.
Previous studies identified an increase in the amount of
proteoglycan in the tibial cartilage of 16–19 week old
STR/ort mice and in the expression of aggrecan mRNA,
compared to CBA mice which do not develop OA lesions6,8.
This is followed by a decrease in proteoglycan content8
which is also detected by loss of alcian blue staining of the
cartilage matrix4. Matrix metalloproteinases (MMPs) are
thought to be the major mediators of cartilage degradation9
and we have detected MMP cleavage of aggrecan and
collagen in developing OA in the STR/ort mouse10,11.
Whether or not specific MMPs and their inhibitors undergo
changes in expression at particular times and sites in the
cartilage during development of the disease is unknown.
However, such information could be used to develop new
forms of therapy. Thus the aim of the present study was to
map the expression of mRNA and protein for MMP2,
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OA in the STR/ort mouse. All of these MMPs and TIMPs
have been implicated in the degeneration of cartilage in
human OA12–17.complement of the antisense nucleotide sequence (MMP3,
MMP13, MT1-MMP and TIMP1), while for other probes it
was a scrambled version of the antisense nucleotide
sequence (MMP2, MMP7, MMP8, MMP9 and TIMP2)
(Table I).
The probes were prepared commercially (VH Bio Ltd,
U.K or Genosys Ltd, Cambridge, U.K.) to contain one
molecule of digoxygenin-dUTP at both the 3′ and 5′ ends.
All pairs of antisense and sense probes were checked by
dot blots with anti-digoxygenin antibody to ensure equiva-
lent labeling with digoxygenin. Probes were stored at
−20°C. A digoxygenin-labeled oligo dT probe (R and D
Systems Ltd, Abingdon, U.K.) was used in control hybrid-
izations to detect poly (A) mRNA. The probes were used
at a concentration of 2.5 ng l−1 in hybridization buffer
(Amersham International PLC, Amersham, U.K.). Hybrid-
ization solution was applied to each section prior to hybrid-
ization overnight in an Omnislide humidity chamber
(Hybaid Ltd, London, U.K.) or a Boekel slide moat (GRI,
Ltd, U.K.) at 42°C. Control sections were exposed to
hybridization solution with no probe, or were RNase treated
prior to hybridization with antisense or sense oligo-
nucleotide. Sections were then washed, initially in 5×SSC
(standard saline citrate, pH 7) and then in 2×SSC, 50%
formamide at 50°C. This was followed by sequential
washes in 2×SSC and 0.1×SSC for 10 min each at room
temperature. The sections were rinsed briefly in a maleic
acid buffer (0.1 M maleic acid, 0.15 M sodium chloride,
pH 7.5) and then blocked with 0.5% blocking solution
(Roche Diagnostics Ltd, Welwyn, U.K.) in maleic buffer for
45 min at room temperature prior to detecting digoxygenin
by reaction with an anti-digoxigenin alkaline phosphatase
antibody (1:100) (Roche Diagnostics) in blocking solution
for 60 min at 20°C. The inclusion of 1% Triton X-100 at this
stage helped to block any non-specific antibody binding.
This was followed by two washes in maleic acid buffer with
0.3% Tween-20 and a single wash in dH2O. Hybridization
signal in the sections was detected with 5-bromo-4-chloro-
indolyl phosphate (BCIP)/nitro blue tetrazolium (NBT)
(Sigma) which was allowed to develop in darkness for 6 h
at 37°C for MMP-13 and overnight for MMP2, MMP3,
MMP7, MMP8, MMP9, MT1-MMP, TIMP1 and TIMP2. The
development was stopped by briefly rinsing the sectionTable I
Sequence of MMP oligonucleotide probes
Target mRNA Sequence (5′–3′) Probe position
MMP2 scrambled CTTGTCATGGATTCTTTAGCTCTACTTGG 1503–1531
MMP2 antisense CCAAATAAACCGGTCCTTGAAGAAGAAGA (NM 008610)
MMP3 sense GGCACTTTTGGCGCAAATCTCTCAGGACTC 1017–1046
MMP3 antisense GAGTCCTGAGAGATTTGCGCCAAAAGTGCC (NM 010809)
MMP7 scrambled GGTGTGGAGTGCCAGATGTTGCAGAATACT 306–335
MMP7 antisense AGTATTCTGCAACATCTGGCACTCCACACC (NM 010810)
MMP8 scrambled CCAGCACCTATTCACTACCTCAAGATGATA 804–833
MMP8 antisense TATCATCTTGAGGTAGTGAATAGGTGCTGG (NM 008611)
MMP9 scrambled TAGCCATTTCGGGTCACGAGATCGGAGGG 502–530
MMP9 antisense TCTCCGTGCTCCGCGACACCAAACTGGAT (NM 013599)
MMP13 sense AAGTGTGACCCAGCCCTATCCCTTGATGCC 860–889
MMP13 antisense GGCATCAAGGGATAGGGCTGGGTCACACTT (NM 008607)
MT1 MMP sense CCCAAAAACCCCGCCTATGGGCCCAACAT 1101–1130
MT1 MMP antisense GATGTTGGGCCCATAGGCGGGGTTTTGGG (NM 008608)
TIMP1 sense TGATTCGTGGGGAACCCATGAATTTAGCCC 131–160
TIMP1 antisense GGGCTAAATTCATGGGTTCCCCACGAATCA (NM 011593)
TIMP2 scrambled AACGCCTCGCGCACCAGACCGCACTCGAC 856–884
TIMP2 antisense GGCACCAGGCCAAGTTCTTCGCCTGCATC (NM 011594)Materials and methods
IN SITU HYBRIDIZATION
All glassware was cleaned in 2% absolve (DuPont Ltd,
U.K.) and baked at 200°C. Solutions were prepared using
deionized water treated with 0.1% diethylpyrocarbonate.
Solutions were autoclaved before use. Groups of six male
STR/ort mice were analysed at age 12, 20, 25, 30 and
35 weeks. Two age- and sex-matched CBA mice were used
as controls at each age. Tissues from each mouse were
sufficient to carry out in situ hybridizations with one or, at
most, two different mRNA probes (see below) so overall
sections from 250 STR/ort mice and 50 CBA mice were
analysed. Serial unfixed and undecalcified sections of
10 m were cut through the whole knee joint using a
cryostat with an automatic drive to ensure sections of
constant thickness7. The sections were flash-dried on to
electrostatically charged glass slides (BDH Ltd., Poole,
U.K.) and stored dry at −70°C. Sections were thawed at
room temperature and fixed in freshly prepared 4% para-
formaldehyde in phosphate buffered saline (PBS) for
20 min. They were washed twice in PBS for 5 min and
digested with proteinase K (20 g ml−1) in 50 mM Tris HCl
buffer, 5 mM EDTA, pH 8, for 10 min at 37°C, after which
they were washed in PBS, refixed in 4% paraformaldehyde
for 20 min and rinsed in distilled water (dH2O). The
sections were treated with 0.25% acetic anhydride in 0.1 M
triethanolamine HCl, pH 8 for 10 min, washed twice in PBS
and air-dried prior to hybridization. Oligonucleotide sense
and antisense probes for gelatinase A (MMP2), stromelysin
(MMP3), matrilysin (MMP7), neutrophil collagenase
(MMP8), gelatinase B (MMP9), collagenase-3 (MMP13),
membrane type 1 metalloproteinase (MMP14/ MT1-MMP),
TIMP1 and TIMP2 were designed from the murine
gene sequences using Lasergen software (DNAstar Inc,
Madison, U.S.A.) to avoid cross-hybridization with other
MMPs18. In some cases the sense probe was the reverse
724 J. Flannelly et al.: Metalloproteinase expression in murine osteoarthritistwice with dH2O, drying in air and mounting in aqueous
mountant.
Hybridization signals were graded independently by two
observers using the following scale; nil (−), weak (+/−),
positive (+) or strongly positive (+ +). The sections were
also graded histologically for evidence of osteoarthritic
damage to the articular cartilage as described previously by
(7). Grade 0=no change in cartilage; 1=roughened articu-
lar surface and minor fibrillations; 2=fibrillations down to
zone 2 and some loss of surface lamina; 3=loss of surface
lamina and fibrillations extending down to the calcified
cartilage; 4=major fibrillations and cartilage erosion down
to the subchondral bone; 5=major fibrillations and erosion
of up to 80% of the cartilage; 6=greater than 80% loss of
cartilage; NC=no cartilage present.MMP3
MMP3 mRNA is expressed in areas of intact STR/ort
cartilage and in CBA cartilage at all ages. Expression isIMMUNOHISTOCHEMISTRY
In preliminary experiments approximately 10 STR/ort
mice (aged 12–50 weeks) were analysed for MMP2, 3, 7, 9,
MT1-MMP and TIMP1 and 2 by immunohistochemistry. For
MMP13, a total of 32 STR/ort mice (aged 6 days to 52
weeks) and 14 CBA mice (aged 12–50 weeks) were
examined. However, due to generally low expression levels
of MMPs and TIMPs, a further series of experiments was
carried out in which knee joints were treated with monensin
to block MMP and TIMP protein secretion from the cell,
thereby facilitating their detection in chondrocytes19. The
following groups of mice were probed for MMP2, 7, 9,
MT1-MMP and TIMPs 1 and 2: STR/ort males aged 9 (×4),
17 (×3), 25 (×3), 30 (×2), 35 (×2), 38 (×2) weeks and CBA
males aged 12 (×2), 24 (×3) and 30 (×3) weeks. For
MMP3 and MMP13 STR/ort males aged 9 (×4), 17 (×3), 19
(×1), 21 (×2), 25 (×3), 28 (×1), 30 (×2), 35 (×2), 37 (×3),
38 (×2), 40 (×1) and 46 (×1) weeks were evaluated (total
25), as well as the CBA males above. The knee joints were
dissected out as described previously7. The anterior pos-
ition of the tibia was marked with indelible ink and the joint
diarticulated by removal of the patella and femur. The
disarticulated tibia was then maintained for 24 h at 37°C in
serum free Dulbecco’s modified Eagles medium containing
5 M monensin (Sigma, Dorset, U.K.). The joints were
then chilled and sectioned as described above. Sections
were stained for matrix metalloproteinases and their
inhibitors using either sheep polyclonal antibodies to
murine MMPs 220, 321, 722, 921, 1323 (two different anti-
bodies, K73/6, L29/6), TIMP1 (R. Hembry et al., in prep-
aration) and TIMP224, a goat polyclonal to murine
MMP1325 (gift from Professor Yves Eeckhout, Universite´
Catholique de Louvain and ICP, Brussels Belgium), or a
mouse monoclonal antibody to MT1-MMP, a gift from
Professor Sato, Kanazawa University, Japan26. The char-
acterization of each antibody by Western blotting and use
in immunolocalization is given in the reference.
The protocol for detecting tissue antigens using the
sheep polyclonal antibodies followed that described by
Fernandes et al.27 with modifications. Sections were first
digested with protease-free chondroitin ABC lyase (ICN
Biomedicals, Inc; 0.02 units per ml, 0.1 M Tris-HCl, pH 8.0,
containing 0.03 M sodium acetate) for 30 min at 37°C,
washed in PBS and further permeabilized with 0.3% Triton
X-100 in PBS for 30 min. Slides were then incubated
with 2% normal swine serum (Dako), 0.5% skimmed milk
(Marvel), 0.3 % Triton X-100, in PBS for 2 h. The blocking
solution was drained off the slides and the sections incu-
bated overnight at 4°C with the relevant primary antibody ata concentration of 50g ml−1. Normal sheep serum used at
the same concentration acted as a control. After washing
with PBS, sections were incubated for 1 h with a swine anti
sheep FITC-conjugated secondary28 antibody diluted 1 in
100 in PBS containing 5% swine serum. Sections were
then washed in PBS, mounted in Vectorshield containing
propidium iodide (Vector Laboratories, CA, U.S.A.) to coun-
terstain the nuclei, and viewed using an Olympus Provis
microscope. The same protocol was used for the goat
polyclonal antibody to MMP13 but rabbit serum was
substituted for swine serum and detection was with a
rabbit antigoat FITC conjugated secondary antibody
(Dako). Preimmune goat serum was used as a control.
MT1-MMP protein was detected using a mouse mono-
clonal antibody (100 g ml−1) and the Vectorlab MOM
kit with visualization by diaminobenzidine (Vector
Laboratories). Preabsorption of the antibody with the
immunogenic peptide (1 mg ml−1) was used as a
control. Sections were viewed using an Olympus Provis
microscope and brightfield illumination.Results
Both the STR/ort and CBA strains of mice showed in situ
hybridization signals for MMP2, MMP3, MMP7, MMP9,
MMP13, MT1-MMP and TIMP2 mRNA in chondrocytes of
the medial and lateral tibial cartilage, whereas mRNAs for
MMP8 and TIMP1 were not detected. Expression was
always much more intense in lesion-free cartilage of STR/
ort mice than in normal cartilage in CBA mice. Signal was
not observed when sections were incubated with hybridiz-
ation buffer in the absence of any antisense oligonucleotide
probe, or when the sections were treated with ribonuclease
prior to hybridization. Some sections hybridized with sense
oligonucleotides gave a weak signal but in every case this
was much lower than that observed with the corresponding
antisense probe. Chondrocytes in the cartilage of all STR/
ort and CBA mice hybridized with an oligo DT probe (results
not shown).MMP2
MMP2 mRNA is expressed throughout the full depth of
the medial and lateral tibial cartilage of both CBA and
STR/ort mice, with high expression in the superficial and
transitional zones. However, expression is always much
stronger in the STR/ort cartilage [Fig. 1(a),(b)]. There
appears to be no difference in the level, or pattern of MMP2
expression in areas with early or late histopathological
lesions [e.g. Fig. 1(c)]. Hybridization with an MMP2 sense
probe [Fig. 1(d)], or with the antisense oligonucleotide after
RNase treatment (not shown) did not give a signal. No
MMP2 protein was detected in the tibial plateaus of either
CBA or STR/ort mice, irrespective of whether cartilage
lesions were present or not [Fig. 2(a)]. The immunostained
sections were indistinguishable from control sections incu-
bated with sheep IgG [Fig. 2(b)]. Positive staining for
MMP2 was always seen in bone marrow cells of both
strains of mice, indicating that the immunodetection system
worked [Fig. 2(c)].
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mice than in CBA mice. The highest level of MMP3 tran-
scripts is found generally throughout the full depth of
articular cartilage in the central region of the tibial plateau
[Fig. 3(a)]. Damaged cartilage usually exhibits a strong
hybridization signal at the surface where the tissue is intact,
although the occurrence of this varies considerably
between animals [e.g. Fig. 3(b) and (c)]. In contrast MMP3
mRNA expression is frequently reduced in the cells sur-
rounding an OA lesion even though transcripts are
observed in other cells throughout the depth of the cartilage
[Fig. 3(b)].
MMP3 protein is detected in most medial and lateral
tibial cartilages of both STR/ort and CBA mice at all ages
[Fig. 2(d)]. The strongest MMP3 immunostaining is associ-
ated with middle to upper zone chondrocytes in both
strains of mice. However, no staining for MMP3 protein
is seen in STR/ort chondrocytes adjacent to OA lesions
[Fig. 2(e)], correlating with loss of mRNA in these cells.
Interestingly, chondrocytes located 50 m distant from
lesions express MMP3 protein [Fig. 2(f)] as in mice with no
OA, demonstrating the focal nature of the disease.MMP 13
There is only weak expression of MMP13 mRNA in CBA
tibial cartilage [Fig. 6(a)]. In marked contrast MMP13 is
expressed strongly in the mid and deep zone chondrocytes
of lesion free medial cartilage of STR/ort mice at all ages
from 12–35 weeks. Expression is particularly intense in
the central region of the medial tibial plateau cartilage
[Fig. 6(b)]. Generally the lateral tibial plateau chondrocytes
of STR/ort mice also show high levels of MMP13 expres-
sion in lesion free medial cartilage [Fig. 6(c)], although the
signal is always stronger in the medial cartilage. With the
development of histopathological lesions in the medial
cartilage there are very distinct decreases in MMP13
mRNA expression, as in chondrocytes in damaged areas
[Fig. 6(d)]. mRNA levels increase progressively in cells the
further away they are from the lesion [Fig. 6(e)]. Similarly
MMP13 mRNA levels were decreased in the proximity of
any lesions present in the lateral cartilage.
MMP13 protein is always detected in the cells just below
the tidemark in both strains of mice at all ages studied
[Fig. 2(j)]. Exactly the same pattern of immunostaining was
seen in the calcified cartilage with all three MMP13 anti-
bodies used. In contrast, in the 25 STR/ort mice examined,
immunostaining was detected in hyaline articular cartilage
of only one 38-week-old animal. This was the same one
that was positive for MMP7. However, while there was
positive staining in the lateral cartilage (OA grade=0) of this
mouse, there was none in the medial cartilage (OA
grade=4). Moreover, the MMP13 immunostain was mainly
in the lateral plateau chondrocytes just below the super-
ficial zone [Fig. 2(k)] and did not therefore colocalize with
the general pattern of elevated mRNA expression in the mid
and deep zone chondrocytes in STR/ort mice. Eight other
STR/ort mice aged 35–46 weeks showed no immunoposi-
tive staining for MMP13 in either the lateral or the medial
tibial cartilage. With the exception of one mouse that was
unaffected by OA lesions, these animals had grade 3–5 OA
lesions in the medial tibial cartilage and one had a grade 1Fig. 1. MMP2 expression in murine medial tibial cartilage detected by in situ hybridization with an antisense oligonucleotide probe (a)–(c).
(a) 24-week CBA, (b) 24-week STR/ort with no OA lesions, (c) 24-week STR/ort with grade 3 lesions, (d) Adjacent section to that in frame
B/C but hybridized with MMP2 sense oligonucleotide probe. AC=articular cartilage. Original magnification ×50.MMP7
Both CBA and STR/ort chondrocytes throughout the
depth of the cartilage express MMP7 mRNA at all ages.
Again expression levels are higher in STR/ort [Fig. 4(a)]
than in CBA mice (not shown). The level of mRNA expres-
sion decreases in areas surrounding histopathological
lesions [Fig. 4(a),(b)]. MMP7 protein was not detected in
any medial cartilages and only in one lateral cartilage in a
38-week-old STR/ort mouse. Here, as with the mRNA, it
was expressed throughout the full depth of the cartilage
[Fig. 2(g)].MMP8
No MMP8 mRNA was detected in tibial chondrocytes in
either STR/ort or CBA strain mice of any age. Thus MMP8
protein expression was not investigated.MMP9
MMP9 mRNA is expressed at low levels at all ages,
throughout the full depth of the cartilage in CBA and
STR/ort mice [Fig. 5(a)]. Signal with the antisense probe
was greater than with the sense probe [Fig. 5(b)]. However,the level of mRNA expression is decreased in chondrocytes
adjacent to histopathological lesions compared to that in
cells in areas of intact cartilage from the same tibial plateau
[Fig. 5(c)]. MMP9 protein was not detected in the tibial
articular cartilage of any of the mice studied [Fig. 2(h)] but
it was present in both resting and hypertrophic chondro-
cytes of the growth plate [Fig. 2(i)] and in bone marrow cells
(not shown) of both strains, confirming that the antibody
reacts with the protein in the cryosections.
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was observed in the hyaline cartilage of any of the CBA
mice.TIMP1
TIMP1 mRNA and protein were not detected in either
STR/ort or CBA mice at any age.Fig. 2. Immunolocalization of MMPs in tibial articular cartilage of STR/ort mice where green fluorescence is MMP protein, red fluorescence
is nuclei counterstained with propidium iodide and yellow fluorescence where the green and red combine. (a) and (b) are serial sections of
medial cartilage from a 35-week mouse immunostained with MMP2 and control sheep IgG respectively and showing no protein. (c) Positive
MMP2 immunostain in bone marrow cells (↓) from the same mouse as in (a) and (b). (d) Positive MMP3 immunostain in the middle to upper
zones of a 25-week STR/ort mouse. (e) No MMP3 immunostain next to an OA lesion (↓) in a 30-week STR/ort mouse. (f) Positive MMP3
immunostain in a section distant from the lesion in the same mouse as in (e). (g) Positive MMP7 immunostain throughout the depths of the
lateral cartilage of a 38-week STR/ort mouse. (h) No MMP9 immunostain in the medial cartilage of a 9-week STR/ort mouse. (i) Positive
MMP9 immunostain in the resting and hypertrophic zones of the growth plate of the same mouse as in (h). (j) Positive MMP13 immunostain
in the calcified cartilage of a 17-week STR/ort mouse. (k) Positive MMP13 immunostain in the upper zones of the lateral cartilage of a
38-week STR/ort mouse. CBA mice at all ages showed similar patterns of immunostain to STR/ort mice except that no MMP7 or MMP13 was
detected in tibial articular cartilage. AC=articular cartilage. RZ=resting zone. HZ=hypertrophic zone. Original magnification ×100.MT1-MMP
MT1-MMP mRNA is expressed at all ages throughout
the full depth of the articular cartilage in STR/ort [Fig. 7(a)]
and CBA mice (not shown). STR/ort expression was
stronger than in CBA mice in both medial and lateral
cartilage. Transcript levels are decreased in regions of
cartilage damage in STR/ort mice [Fig. 7(b)], but are
prominent in the intact cartilage in the same tibial plateau.
MT1-MMP protein was readily detected and is distributed
throughout the full depth of the cartilage in both strains ofmice [Fig. 7(c)]. Immunostaining on the surface of the
cartilage is artifactual since it is still present after pre-
absorption of the antibody with the immunogenic peptide
[Fig. 7(d)]. MT1-MMP staining is reduced in areas adjacent
to OA lesions in STR/ort mice [Fig. 7(e)], while sections
distant from lesions show a pattern of staining similar to
that seen in animals without lesions [Fig. 7(f)]. The protein
expression of MT1-MMP correlates exactly with the mRNA
expression pattern.
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Both CBA and STR/ort mice expressed low levels of
TIMP2 mRNA at all ages, throughout the full depth of the
medial and lateral tibial plateau [Fig. 8(a)]. Interestingly
there are no differences in the TIMP2 mRNA level in
chondrocytes surrounding early or late histopathological
OA lesions [Fig. 8(b)]. TIMP-2 protein could not be detected
at any age in either strain of mice (not shown).
The results of the in situ hybridization and immuno-
localization of all MMPs and TIMPS investigated are
summarized in Table II.the helical region of type II collagen in characteristic posi-
tions leaving new N- and C-terminal amino acid sequences
either side of the cleavage site. These constitute
neoepitopes29. We have shown that MMPs, including col-
lagenase, are active in the tibial articular cartilage of CBA
and STR/ort mice because such neoepitopes can be
detected in the tissue10,11. The C-terminal neoepitope
created by MMP cleavage of aggrecan between
VDIPEN341–342FFGVF of the core protein is present in the
pericellular matrix of deep zone tibial chondrocytes of
normal cartilage in both strains of mice, indicating a physio-
logical role for these enzymes in the tissue. However, with
the development of OA lesions in the STR/ort mouse,
marked increases in the level of VDIPEN neoepitope were
observed in the pericellular matrix of chondrocytes through-
out the full depth of the cartilage and in matrix more distant
from cells but adjacent to the lesions themselves10. A
similar distribution of aggrecan neoepitopes has beenFig. 3. MMP3 expression in murine medial tibial cartilage detected by in situ hybridization. (a) 35-week STR/ort with no OA lesions,
(b) 35-week STR/ort with grade 4 lesion, (c) 30-week STR/ort with grade 3 lesion. Original magnification ×50.Fig. 4. MMP7 expression in 30-week medial tibial cartilage detected by in situ hybridization. (a) 30-week STR/ort with no OA lesions,
(b) 30-week STR/ort with grade 2 lesions. Original magnification ×50.Fig. 5. MMP9 expression in 24-week STR/ort medial tibial cartilage detected by in situ hybridization. (a) antisense probe with no OA lesions,
(b) no OA lesions, sense probe, (c) grade 4 lesion, antisense probe. Original magnification ×50.Discussion
The principal matrix degrading proteinases in articular
cartilage are thought to be matrix metalloproteinases
(MMPs)17. MMPs cleave the core protein of aggrecan and
728 J. Flannelly et al.: Metalloproteinase expression in murine osteoarthritisreported in normal and osteoarthritic human articular carti-
lage30. While cleavage of the helical region of type II
collagen could not be detected in normal murine tibial
cartilage with an antibody recognizing the neoepitope
resulting from collagenase activity, this neoepitope was
present in the extracellular matrix adjacent to osteoarthritic
lesions11. Similarly, collagen cleavages generated by colla-
genase activity have been demonstrated in human osteo-
arthritic articular cartilage31. Thus, there can be little doubt
that members of the matrix metalloproteinase family play a
significant role in both normal cartilage matrix turnover and
in accelerated breakdown in OA. Whether all or only somemembers of this large family of proteinases are involved in
the latter process is clearly an important question for the
design of new therapeutic approaches in OA, but there is
little information available about this. One approach to
answering it is to map the expression of known MMPs in
articular cartilage before and at various stages during the
development of OA. The main conclusion from the present
study is that mRNA levels for each of the MMPs investi-
gated are increased in the tibial chondrocytes of the STR/
ort mouse compared with those in CBA mice. However,
using immunohistochemistry we were unable to correlate
this finding with corresponding changes in protein levels forFig. 6. MMP13 expression in murine tibial cartilage detected by in situ hybridization (a)–(e). (a) 35-week CBA, (b) 35-week STR/ort medial
tibial plateau cartilage with no OA lesions, (c) 35-week STR/ort lateral tibial plateau cartilage with no OA lesions, (d) 35-week STR/ort medial
tibial plateau cartilage with grade 3 lesions, (e) 35-week STR/ort medial tibial plateau cartilage 50 m distant from (d) with grade 1 lesions.
Original magnification ×50.Fig. 7. MT1-MMP expression in murine medial tibial cartilage detected by in situ hybridization (a)–(b) and immunohistology (c),(d).
(a) 35-week STR/ort with no OA lesions, (b) 35-week STR/ort with grade 4 lesion, (c) Positive MT1-MMP immunostain in a 25-week STR/ort
mouse. (d) Serial section to (c) preabsorbed with immunogenic peptide and showing no immunostain. (e) No MT1-MMP immunostain at the
site of an OA lesion (↓) in a 30-week. Original magnification ×50.
Osteoarthritis and Cartilage Vol. 10, No. 9 729these enzymes, so the mRNA results must be necessarily
interpreted with caution. We discuss the failure to detect
enzyme protein changes below, particularly with respect to
MMP13, which showed very marked increases in its mRNA
pool in STR/ort mice.
Three MMP collagenases have been identified32 and
collagenase activity has been reported in osteoarthritic
cartilage33. They are collagenase 1 (MMP1), collagenase 2
or neutrophil collagenase (MMP8), and collagenase 3
(MMP13). MMP13 has a higher level of activity against type
II collagen, characteristically found in cartilage, than
MMP134. Rodents appear to express MMP13 predomi-
nantly, although a recent report also shows that murine
MMP1 is expressed during embryogenesis35. The oligo-
nucleotide probe for MMP13 used in our in situ hybridiz-
ation studies does not show homology with the murine
MMP1 sequence. In the present in situ hybridization
studies we found much higher expression of MMP13 in the
mid and deep zone tibial chondrocytes of STR/ort mice
than in CBA mice. In contrast, the earliest evidence of
collagen cleavage in the development of STR/ort OA was
detected in areas of roughening of the articular cartilage
surface11. The high level of MMP13 mRNA in STR/ort
cartilage was present from the earliest age investigated
and before histopathological lesions of OA developed. It
decreased in chondrocytes immediately adjacent to well
developed lesions. Transcript levels for several other
MMPs also decreased in these cells and at least some of
them are apoptotic36. MMP13 mRNA has been detected by
in situ hybridization in the deep layer of human articular
cartilage and expression increased in OA and rheumatoid
arthritis37. The enzyme was also located immunochemi-
cally in the deep zone tibial plateau cartilage of dogs in
which OA had been induced experimentally27. Moreover, a
synthetic collagenase inhibitor, Ro32-3555, was reported to
protect against breakdown of cartilage and bone in STR/ort
mice, suggesting involvement of a collagenase in this
model of OA38. However, despite our data indicating a
much higher level of MMP13 gene expression in pre-
lesional STR/ort cartilage than in the CBA strain and the
other evidence suggestive of a role for this enzyme in
the development of OA, we detected its protein only by
immunohistochemistry in the chondrocytes of the lateral
cartilage of one STR/ort mouse. Since eight other STR/ort
mice of similar age had no immunohistochemically detect-
able MMP13 in either the lateral or medial tibial cartilage
(where OA lesions occur most frequently), the one
immunopositive lateral cartilage does not constitute con-
vincing evidence for the involvement of the enzyme in the
disease process. It is noteworthy that two of our anti-
MMP13 antibodies (K73/6 and 1.29/6) detected MMP13
protein by immunohistochemistry in pig articular cartilage
after wounding the latter23. Interestingly, all three anti-
MMP13 antibodies used in the present study bound to aligand in the cells of the calcified zone in which no MMP13
mRNA was evident by in situ hybridization.
There could be several explanations for the failure to
detect MMP13 protein in STR/ort articular cartilage. It may
be synthesized in hyaline cartilage chondrocytes, but in
amounts below the detection level of the immuno-
histochemical method, even though three different anti-
MMP13 antibodies were used. It is noteworthy that we were
also unable to detect either MMP2 or MMP9 in murine
articular cartilage by immunohistochemistry but PBS-
extracts of microdissected tibial plateau cartilage from
either STR/ort or CBA mice showed evidence for the
presence of each enzyme on SDS-PAGE Western blots
and gelatin zymograms (Flannelly et al., unpublished
observations). Thus immunohistochemistry is of lesser
sensitivity for detecting MMPs than these other methods.
However, we were unable to detect MMP13 in such
extracts by either Western blot or by heparin-enhanced
gelatin zymography, a sensitive technique for revealing this
enzyme39.
One speculation for failure to detect extracellular MMP13
immunohistochemically is that after synthesis it may bind to
other proteins, preventing its subsequent detection with
antibodies. Barmina et al.40 have reported that MMP13
binds to, and is internalized by, a variety of cells, including
osteoblasts and fibroblasts. The binding involves a
∼170 kDa protein which may be a specific receptor for
the enzyme. This receptor, Endo-180, and MMP13 are
co-expressed during osteogenesis41. Moreover, Endo180
protein is expressed in tibial articular cartilage chondro-
cytes of both CBA and STR/ort mice, so secreted
MMP13 may be removed rapidly42. However, the current
experiments should have detected intracellular MMP13
accumulated during the monensin block, as well as pre-
existing extracellular MMP13. Since there was no evidence
of intracellular enzyme, none may have been syn-
thesized during the block. MMP13 is known to be only
transiently expressed in some situations, for example,
murine ossification43, potentially complicating its detection
in tissues.
We also considered the possibility that the antibodies
used in immunohistochemistry may not be able to access
antigenic sites in articular cartilage. However, this seems
unlikely because tissues were routinely digested with
chondroitinase ABC and, in pilot experiments, were also
treated with testicular hyaluronidase, proteinase K and
Triton X-100. Thus, if MMP13 mRNA is translated to
protein, the monensin block used in our immunohisto-
chemistry should retain the newly synthesized protein in
the Golgi, where it should be detectable. Moreover, the
anti-MMP13 antibody K73/6 was able to detect MMP13
protein in chondrocytes in wounded pig articular cartilage
and in growth plate of gp130 (delta STAT) mice (Ernst, M.
and Hembry, R.M., unpublished work) which developFig. 8. TIMP2 mRNA expression in murine medial tibial cartilage detected by in situ hybridization. (a) 18-week STR/ort with no OA lesions,
(b) 18-week STR/ort with grade 3 lesions. Original magnification ×50.
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Osteoarthritis and Cartilage Vol. 10, No. 9 731severe joint degeneration. Thus there can be no doubt
about this antiserum’s ability to detect the enzyme in
hyaline cartilage when it is present. We also detected
MMP13 with this antiserum in Western blots of culture
medium of equine articular explant cartilage stimulated with
IL1.
We were able to detect collagen cleavage neoepitopes
in the STR/ort cartilage from the time of development of
very early OA lesions (surface roughening)11. Thereafter,
as fibrillations developed, further collagen degradation was
evident around the edge of the lesion and in the adjacent
extracellular matrix. The mice in the present study included
animals up to 50 weeks of age with OA lesions ranging
from mild to severe. Thus it seems likely that the failure to
detect MMP13 protein in the STR/ort articular cartilage
despite the presence of OA lesions and an apparent
increase in the level of its mRNA pool is due either to one of
the reasons discussed above, or to collagen fibril cleavage
being due to other proteases, as discussed previously11.
mRNAs were detected for several other MMPs in articu-
lar chondrocytes, notably 2, 3, 7, 9 and MT1-MMP. In each
case expression was higher in the STR/ort strain before
and after development of lesions than in CBA cartilage,
except in those chondrocytes immediately adjacent to OA
lesions. mRNA expression of most MMPs occurred
throughout the full depth of the medial and lateral tibial
cartilage, but this was not always the case. For example,
MMP2 (gelatinase A) expression occurs predominantly in
the upper zones whereas MMP9 (gelatinase B) is
expressed throughout the full depth. MMP2 is reported to
have collagenase activity44,45, although this is disputed by
others46. As discussed above, we detected this enzyme
in murine cartilage extracts by techniques other than
immunohistochemistry. It is noteworthy that the prominent
MMP2 mRNA expression in the upper zones fits more
closely with the observed pattern of collagen cleavage in
early OA in the STR/ort mouse11, than does the strong
expression of MMP13 mRNA in the mid and deep zones of
the cartilage.
MMP3 (stromelysin-1) is a possible candidate for
degradation of aggrecan in the early stages of STR/ort OA.
It is expressed as a protein in the superficial zone of
articular cartilage where MMP-generated aggrecan
neoepitopes appear10 and where the earliest lesions
develop4. MMP3 has a wide range of substrates, and is
considered a key enzyme in cartilage catabolism47. As well
as degrading matrix macromolecules it participates in the
activation of other MMPs such as proMMP9 and
MMP1312,48. Although the level of MMP3 protein in CBA
and STR/ort articular cartilage did not differ significantly in
this study, it could, potentially, participate in the osteo-
arthritic process if its activity was inhibited in normal carti-
lage but not so in osteoarthritic tissue. However, no
changes were detected in either of the two TIMPs (1 and 2)
investigated in the study (see below).
MT1-MMP, which has been implicated in the activation of
other proteases49, is expressed as a protein throughout the
tibial cartilages of both CBA and STR/ort mice. The level
of expression appears to be similar in both strains so if
it plays a role in the development of OA it is likely to be
by activation of proenzymes in the diseased cartilage.
However, as the disease progresses and lesions develop,
neither MMP3 nor MT1-MMP proteins are found in
chondrocytes adjacent to the lesion. Similarly these fail
to express mRNAs for a number of MMPs which are
transcribed in chondrocytes distant from the lesions.Protein expression alone, or even changes in the level of
protein expression for an MMP, do not in themselves
necessarily indicate enzyme activity. The control of MMP
activity is complex since these enzymes are secreted
as latent proenzymes and must be activated at the cell
surface or in the matrix to act on extracellular sub-
strate17,49. Even after activation, MMPs are bound by
tissue inhibitors of matrix metalloproteinases (TIMPs),
which inactivate them17. It is believed that a change in the
ratio of MMP:TIMP may occur in disorders such as OA50
where accelerated matrix catabolism occurs. We assessed
the expression of TIMP1 and TIMP2 in the murine articular
cartilage. TIMP1 was not detected at either the mRNA or
protein level, while TIMP2 transcripts were expressed
throughout the full depth of both CBA and STR/ort articular
cartilage. The level of expression appeared unchanged
with the development of lesions. However, no TIMP2 pro-
tein was detected in any murine cartilage. This may have
been for the same reasons discussed for the failure to
detect MMP13 protein. If TIMP2 protein is present but
undetected in the murine cartilages, its level is unlikely
to change during the osteoarthritic process since mRNA
levels did not change. TIMP3 and 4 were not investigated in
this study.
The expression of MMPs and TIMPs is regulated by
growth factors and cytokines51. We have reported pre-
viously that the expression of IL1, IL6, TGF and IGF1
mRNA is markedly elevated in the tibial articular cartilage of
STR/ort mice compared with CBA strain cartilage where
transcripts of these genes could not be detected by in situ
hybridization. Moreover, mRNAs for cytokines and growth
factors were detected in chondrocytes of STR/ort cartilage
before the development of histopathological OA lesions7. It
seems very likely that the different cytokine environment
of the STR tibial cartilage may be a stimulus for the
increased expression of MMP2, MMP3, MMP7, MMP9,
MMP13 and MT1-MMP, which we detected in this tissue by
in situ hybridization. The factor or factors responsible for
promoting a high level of cytokine expression by STR/ort
chondrocytes remains unknown.References
1. Lukoschek M, Boyd RD, Schaffler MB, Burr DB,
Radin EL. Comparison of joint degeneration models.
Surgical instability and repetitive impulsive loading.
Acta Orthop Scand 1986;57:349–53.
2. Walton M. Studies of degenerative joint disease in the
mouse knee joint; scanning electron microscopy.
J Pathol 1977;123:211–17.
3. Walton M. A spontaneous ankle deformity in an inbred
strain of mouse. J Pathol 1978;124:189–94.
4. Mason RM, Chambers MG, Flannelly JK, Gaffen JD,
Dudhia J, Bayliss MT. The STR/ort mouse and its use
as a model of osteoarthritis. Osteoarthritis Cart
2001;9:85–91.
5. Dunham J, Chambers MG, Jasani MK, Bitensky L,
Chayen J. Changes in oxidative activities of chondro-
cytes during the early development of natural murine
osteoarthritis. Br J Exp Pathol 1988;69:845–53.
6. Gaffen JD, Bayliss MT, Mason RM. Elevated aggrecan
mRNA in early murine osteoarthritis. Osteoarthritis
Cart 1997;5:227–33.
7. Chambers MG, Bayliss MT, Mason RM. Chondrocyte
cytokine and growth factor expression in murine
osteoarthritis. Osteoarthritis Cart 1997;5:301–8.
732 J. Flannelly et al.: Metalloproteinase expression in murine osteoarthritis8. Gaffen JD, Gleave SJ, Crossman MV, Bayliss MT,
Mason RM. Articular cartilage proteoglycans in
osteoarthritis STR/ort mice. Osteoarthritis Cart 1995;
3:95–104.
9. Martel-Pelletier J, Pelletier JP. Neutral metallo-
proteases and age related changes in human
articular cartilage. Ann Rheum Dis 1987;46:363–9.
10. Chambers MG, Cox L, Chong L, Suri N, Cover P,
Bayliss MT, et al. Neutral matrix metalloproteinases
and aggrecanases cleave aggrecan in different
zones of normal cartilage but localise in the develop-
ment of osteoarthritic lesions on STR/ort mice.
Arthritis Rheum 2001;44:1455–65.
11. Price JS, Chambers MG, Poole AR, Fradin A, Mason
RM. Comparison of type II collagen cleavage by
collagenase in the naturally occurring STR/ort mouse
model of osteoarthritis with a collagen-induced
inflammatory arthritis model. Osteoarthritis Cart
2002;10:172–179.
12. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-
Pelletier J. The new collagenase, collagenase-3, is
expressed and synthesized by human chondrocytes
but not by synoviocytes. A role in osteoarthritis. J Clin
Invest 1996;97(1):2011–19.
13. Shlopov BV, Lie WR, Mainardi CL, Cole AA,
Chubinskaya S, Hasty KA. Osteoarthritic lesions:
involvement of three different collagenases. Arthritis
Rheum 1997;40:2065–74.
14. Cole AA, Kuettner KE. MMP-8 (neutrophil collagenase)
mRNA and aggrecanase cleavage products are
present in normal and osteoarthritic human articular
cartilage. Acta Orthop Scand Suppl 1995;266:
98–102.
15. Cole AA, Chubinskaya S, Schumacher B, Huch K,
Szabo G, Yao J, et al. Chondrocyte matrix
metalloproteinase-8. Human articular chondrocytes
express neutrophil collagenase. J Biol Chem 1996;
27:11023–6.
16. Cawston T. Matrix metalloproteinases and TIMPs:
properties and implications for the rheumatic
diseases. Mol Med Today 1998;4:130–7.
17. Cawston T, Billington C, Cleaver C, Elliott S, Hui W,
Koshy P, et al. The regulation of MMPs and TIMPs in
cartilage turnover. Ann N Y Acad Sci 1999;30(878):
120–9.
18. Docherty AJ, Murphy G. The tissue metalloproteinase
family and the inhibitor TIMP: a study using cDNAs
and recombinant proteins. Ann Rheum Dis
1990;49:469–79.
19. Hembry RM, Murphy G, Cawston TE, Dingle JT,
Reynolds JJ. Characterization of a specific anti-
serum for mammalian collagenase from several
species: immunolocalization of collagenase in rabbit
chondrocytes and uterus. J Cell Sci 1986;81:
105–23.
20. Hipps DS, Hembry RM, Docherty AJ, Reynolds JJ,
Murphy G. Purification and characterization of
human 72-kDa gelatinase (type IV collagenase). Use
of immunolocalisation to demonstrate the non-
coordinate regulation of the 72-kDa and 95-kDa
gelatinases by human fibroblasts. Biol Chem Hoppe
Seyler 1991;372:287–96.
21. Dew G, Murphy G, Stanton H, Vallon R, Angel P,
Reynolds JJ, et al. Localization of matrix metallopro-
teinases and TIMP-2 in resorbing mouse bone. Cell
Tissue Res 2000;299:385–94.22. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL.
Immunolocalization studies on six matrix metallo-
proteinases and their inhibitors, TIMP-1 and TIMP-2,
in synovia from patients with osteo- and rheumatoid
arthritis. Ann Rheum Dis 1995;54:25–32.
23. Hembry RM, Dyce J, Driesang I, Hunziker EB, Fosang
AJ, Tyler JA, et al. Immunolocalization of matrix
metalloproteinases in partial-thickness defects in pig
articular cartilage. J Bone Joint Surg Am 2001;83-
A:826–38.
24. Ward RV, Atkinson SJ, Reynolds JJ, Murphy G. Cell
surface-mediated activation of progelatinase A:
demonstration of the involvement of the C-terminal
domain of progelatinase A in cell surface binding and
activation of progelatinase A by primary fibroblasts.
Biochem J 1994 15;304:263–9.
25. Delaisse JM, Eeckhout Y, Neff L, Francois-Gillet C,
Henriet P, et al. (Pro)collagenase (matrix metal-
loproteinase-1) is present in rodent osteoclasts and
in the underlying bone-resorbing compartment. J Cell
Sci 1993;106:1071–82.
26. Sato H, Takino T, Okada Y, Cao J. Shinagawa A,
Yamamoto E, et al. A matrix metalloproteinase
expressed on the surface of invasive tumour cells.
Nature 1994;370:61–5.
27. Fernandes JC, Martel-Pelletier J, Lascau-Coman V,
Moldovan F, Janovic D, Raynauld JP, et al.
Collagenase-1 and collagenase-3 synthesis in nor-
mal and early experimental osteoarthritic canine car-
tilage: an immunohistochemical study. J Rheumatol
1998;25:1585–94.
28. Hembry RM, Murphy G, Reynolds JJ. Immunolocaliz-
ation of tissue inhibitor of metalloproteinases (TIMP)
in human cells. Characterization and use of a specific
antiserum. J Cell Sci 1985;73:105–19.
29. Croucher LJ, Hollander AP. Differential detection of
type II collagen N-terminal and C-terminal denatur-
ation epitopes in degrading cartilage. Mol Pathol
1999;52:323–31.
30. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner
LA, Hutchinson NI, et al. Aggrecan degradation in
human cartilage. Evidence for both matrix metallo-
proteinase and aggrecanase activity in normal,
osteoarthritic, and rheumatoid joints. J Clin Invest
1997;100:93–106.
31. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne
R, Poole AR. Damage to type II collagen in aging and
osteoarthritis starts at the articular surface, originates
around chondrocytes, and extends into the cartilage
with progressive degeneration. J Clin Invest 1995;
96:2859–69.
32. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco
R, Toliva J, et al. Molecular cloning and expression of
collagenase-3, a novel human matrix metalloprotein-
ase produced by breast carcinomas. J Biol Chem
1994;269:16766–73.
33. Freemont AJ, Byers RJ, Taiwo YO, Hoyland JA. In situ
zymographic localisation of type II collagen degrad-
ing activity in osteoarthritic human articular cartilage.
Ann Rheum Dis 1999;58:357–65.
34. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow
LL, Yocum SA, Rosner PJ, et al. Cloning, expression,
and type II collagenolytic activity of matrix metal-
loproteinase-13 from human osteoarthritic cartilage.
J Clin Invest 1996;97:761–8.
Osteoarthritis and Cartilage Vol. 10, No. 9 73335. Balbini M, Fueyo A, Kna¨uper V, Lopez JM, Alvarez J,
Sanchez LM, et al. Identification and enzymatic char-
acterization of two diverging murine counterparts of
human interstitial collagenase (MMP-1) expressed at
sites of embryo implantation. J Biol Chem
2001;276:10253–62.
36. Oue Y, Chambers MG, Bayliss MT, Mason RM.
Chondrocyte apoptosis accompanies lesion develop-
ment in murine osteoarthritis. Transactions Com-
bined Orthopaedic Research Society Meeting, Japan
1998 (Abstract).
37. Moldovan F, Pelletier JP, Hambor J, Cloutier JM,
Martel-Pelletier J. Collagenase-3 (matrix metallo-
protease 13) is preferentially localized in the deep
layer of human arthritic cartilage in situ: in vitro
mimicking effect by transforming growth factor beta.
Arthritis Rheum 1997;40:1653–61.
38. Brewster M, Lewis EJ, Wilson KL, Greenham AK,
Bottomley KM. Ro 32-3555, an orally active colla-
genase selective inhibitor, prevents structural dam-
age in the STR/ort mouse model of osteoarthritis.
Arthritis Rheum 1998;41:1639–44.
39. Yu WH, Woessner JF Jr. Heparin-enhanced zymo-
graphic detection of matrilysin and collagenases.
Anal Biochem 2001;293:38–42.
40. Barmina OY, Walling HW, Fiacco GJ, Freije JMP,
Lo´pez-Otı´n C, Jeffrey JJ, Partridge NC.
Collagenase-3 binds to a specific receptor and
requires the low density lipoprotein receptor-related
protein for internalization. J Biol Chem 1999;274:
30087–93.
41. Engelholm LH, Nielsen BS, Netzel-Arnett S, Solberg
H, Chen X-D, Garcia JML, et al. The urokinase
plasminogen activator receptor-associated protein/
endo180 is coexpressed with its interaction partners
urokinase plasminogen activator receptor and matrix
metalloprotease-13 during osteogenesis. Lab Invest
2001;81:1403–14.
42. Chambers M, Howard M, Mistry D, Yarwood H, Isacke
C, Mason RM. Endo180, an endocytic receptor is
expressed on chondrocytes and is regulated by
IL-1. Orthop Res Soc Trans 2001;26:0408.43. Tuckermann JP, Pittoiss K, Partridge NC, Merregaert
J, Angel P. Collagenase-3 (MMP-13) and integral
membrane protein 2a (Itm2a) are marker genes of
chondrogenic/osteoblastic cells in bone formation:
sequential temporal, and spatial expression of Itm2a,
alkaline phosphatase, MMP-13, and osteocalcin in
the mouse. J Bone Miner Res 2000;15:1257–65.
44. Aimes RT, Quigley JT. Matrix metalloproteinase-2 is an
interstitial collagenase. Inhibitor-free enzyme cata-
lyzes the cleavage of collagen fibrils and soluble
native type I collagen generating the specific 3/4- and
1/4-length fragments. J Biol Chem 1995;270:5872–6.
45. Patterson ML, Atkinson SJ, Knauper V, Murphy G.
Specific collagenolysis by gelatinase A, MMP-2, is
determined by the hemopexin domain and not the
fibronectin-like domain. FEBS Lett 2001;503:158–62.
46. Seltzre JL, Eisen AZ. Native type I collagen is not a
substrate for MMP2 (gelatinase A). J Invest Dermatol
1999;112:993–4.
47. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix
metalloproteinase degradation of elastin, type IV col-
lagen and proteoglycan. A quantitative comparison of
the activities of 95 kDa and 72 kDa gelatinases,
stromelysins-1 and -2 and punctuated metallo-
proteinase (PUMP). Biochem J 1991;277:277–9.
48. Knauper V, Murphy G, Tschesche H. Biochemical
characterization of human collagenase-3. J Biol
Chem 1996;271:1544–50.
49. Murphy G, Stanton H, Cowell S, Butler G, Knauper V,
Atkinson S, et al. Mechanisms for pro matrix
metalloproteinase activation. APMIS 1999;107:38–
44.
50. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Serum
levels of collagenase, stromelysin-1, and TIMP-1.
Age- and sex-related differences in normal subjects
and relationship to the extent of joint involvement and
serum levels of antigenic keratan sulfate in patients
with osteoarthritis. Arthritis Rheum 1994;37:1774–83.
51. Matrisian LM, Hogen BL. Growth factor-regulated pro-
teases and extracellular matrix remodeling during
mammalian development. Curr Top Dev Biol 1990;
24:219–59.
